Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05239533
Other study ID # 21-328
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 16, 2022
Est. completion date March 2025

Study information

Verified date December 2023
Source Memorial Sloan Kettering Cancer Center
Contact Darren Feldman, MD
Phone 646-888-4740
Email Feldmand@MSKCC.ORG
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.


Recruitment information / eligibility

Status Recruiting
Enrollment 41
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Locally advanced unresectable or metastatic RCC with either a component of clear cell histology or carbonic anhydrase-IX (CAIX) expression by immunohistochemistry (IHC) i. Archival tumor tissue will be requested from patients who have undergone biopsy or tumor resection as part of routine clinical care prior to study participation to confirm diagnosis. Patients may undergo pre-treatment biopsy during the screening period if archival tissue is insufficient for baseline analysis. Tumor specimen may include nephrectomy or metastatic site specimen. 2. At least one evaluable metastatic lesion as defined by RECIST 1.1 on zirconium-89 (89Zr)-girentuximab PET/CT 3. At least one prior line of systemic therapy, including at least one prior treatment with anti PD-1 or PD-L1antibody 4. Age =18 years 5. KPS = 70 6. Adequate performance status and adequate organ function: 1. ANC = 1500 cells/µL 2. WBC = 2500/µL 3. Lymphocyte count = 500/µL 4. Platelet count =100,000/µL (without transfusion within 2 weeks prior to Cycle 1, Day 1; thrombopoietic agent use is allowed) 5. Hemoglobin =9.0 g/dL (patients may be transfused or receive erythropoietic treatment to meet this criterion) 7. AST, ALT, and alkaline phosphatase = 2.5 x ULN, with the following exceptions: 1. Patients with documented liver metastases: AST and/or ALT = 5 x ULN 2. Patients with documented liver or bone metastases: alkaline phosphatase = 5 x ULN 8. Serum bilirubin = 2 x ULN a) Patients with known Gilbert disease who have serum bilirubin level = 3 x ULN may be enrolled. 9. INR and aPTT = 1.5 x ULN a) This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. 10. Creatinine clearance = 40mL/min, as measured by the Cockcroft-Gault formula. 11. Women of childbearing potential and men are advised to practice double-barrier contraception until a minimum of 6 months after IV 89Zr-girentuximab or177Lu-girentuximab administration. Women of childbearing potential are advised to practice double-barrier contraception until a minimum of 5 months after nivolumab. 12. Signed consent form by the participant or a legally authorized representative (LAR). Exclusion Criteria: 1. Renal cell carcinoma with no histological evidence of any component of clear cell features. Note: Unclassified RCC with clear cell features is eligible for inclusion. 2. Prior treatment with 177Lu- girentuximab. 3. Known hypersensitivity to girentuximab or DFO (desferoxamine). 4. Exposure to murine or chimeric antibodies within the last 5 years. 5. Previous administration of any radionuclide within 10 half-lives of the same. 6. Radiotherapy for RCC within 14 days prior to Cycle 1, Day 1 except for single-fraction radiotherapy given for the indication of pain control which should be given at least 48 hours prior to C1D1. 7. Active untreated metastases to the brain >1cm or symptomatic (of any size) 8. Active untreated metastases to the spinal cord or leptomeningeal disease 9. Patients with uncontrolled pain who are not on a stable pain regimen . 10. History of steroid requirement > 10 mg daily prednisone in the past 2 years for autoimmune comorbidities. 11. Prior checkpoint inhibitor therapy discontinued due to immune related adverse events. 12. Anti-cancer therapy within 2 weeks prior to enrollment. 13. Uncontrolled hypercalcemia (= 1.5 mmol/L ionized calcium or Ca = 12 mg/dL or corrected serum calcium = ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab. 14. Malignancies other than RCC within 3 years prior to Cycle 1, Day 1, except for those with a negligible risk of metastasis or death, treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent, non-muscle-invasive urothelial carcinoma). 15. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. 16. HIV infection if not well-controlled with antiretroviral therapy 17. Patients with active or chronic hepatitis B or hepatitis C infection. 18. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, unstable angina, or EF < 50%. 19. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate. 20. History of stroke or transient ischemic attack within 6 months prior to Cycle 1, Day 1. 21. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1. 22. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation). 23. Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding . 24. Evidence of abdominal free air not explained by paracentesis or recent surgical procedure. 25. Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture. 26. Major surgery within 4 weeks prior to enrollment (biopsy or line placement can be performed up to 24 hours prior to enrollment). 27. Pregnant and lactating women. 28. Patients in whom nivolumab treatment is not feasible for any reason (including financial/insurance).

Study Design


Intervention

Drug:
177Lu-labeled-girentuximab
The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. >/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2 Once the MTD is established, a Simon two-stage optimal design will commence.
Nivolumab
Nivolumab 240mg q2wk
Diagnostic Test:
89Zr-girentuximab PET/CT
All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
177Lu whole body (WB) planar and SPECT/CT scans
177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab

Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey
United States Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack New York
United States Memorial Sloan Kettering Westchester (Limited Protocol Activites) Harrison New York
United States Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York
United States Memorial Sloan Kettering Nassau (Limited Protocol Activites) Uniondale New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximal tolerated dose (MTD) of 177Lu-girentuximab To determine the maximal tolerated dose (MTD) of 177Lu-girentuximab when given in combination with nivolumab (safety lead-in) 24 (+/- 2) weeks
Primary Overall Response Rate/ORR efficacy of the combination at the MTD of 177Lu-labelled girentuximab in patients with advanced ccRCC as assessed by best ORR by 24 (+/- 2) weeks by Response Evaluation Criteria In Solid Tumors (RECIST v1.1). 24 (+/- 2) weeks
See also
  Status Clinical Trial Phase
Completed NCT00541008 - Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Withdrawn NCT00769990 - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Phase 1/Phase 2
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Recruiting NCT00301990 - Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Phase 2
Completed NCT00467077 - Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer Phase 2
Completed NCT00098943 - NGR-TNF in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT00089102 - Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer Phase 2
Terminated NCT00899860 - Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer N/A
Completed NCT00021021 - RPI.4610 in Treating Patients With Metastatic Kidney Cancer Phase 2
Completed NCT00006968 - Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer Phase 1/Phase 2
Completed NCT00006022 - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer Phase 1